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Methylmalonic acid (MMA) accumulates in the body
in cases of cobalamin (vitamin B12) deficiency be-
cause of impaired metabolization of methylmalonyl
CoA to succinyl CoA by methylmalonyl CoA-mutase,
a cobalamin-dependent enzyme. Therefore, MMA
represents a functional marker of cobalamin deficien-
cy (1). It is widely accepted that MMA measurement
is useful and necessary if serum cobalamin concen-
trations between 150 and 300 pg/mL are found, over-
coming the limited reliability of serum cobalamin
measurement in the lower concentration range (2–4).
Despite good evidence for the usefulness of MMA
measurement, tests are rarely requested in many
countries and are offered by only a few laboratories.
This particularly applies for measurement of urinary
MMA, which clearly represents the sample material
of choice; impaired renal function is associated with
increased serum and plasma MMA concentrations,
irrespective of the cobalamin status (5). In contrast,
measurement of urinary MMA concentrations and cal-
culation of the ratio of urinary MMA to urinary cre-
atinine is essentially independent of individual renal
function.
Quantification of MMA in both serum and urine is
technically demanding and gas chromatography (GC)
or liquid chromatography (LC) isotope dilution mass
spectrometry methods are mandatory. So far, no
matrix-based materials for MMA assay calibration
and continuous quality control are commercially
available. After initial studies (6, 7), proficiency testing
programs for serum and plasma MMA measurement
were implemented in Europe and the USA. For uri-
nary MMA measurement, however, no external qual-
ity control programs have been implemented so far.
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With this letter we would like to announce an inter-
national pilot project for the implementation of a
proficiency testing program for urinary MMA meas-
urement. The main objective of this study is to assess
the reliability of analytical methods used for MMA
measurement and to investigate the degree of inter-
laboratory variability of urinary MMA measurement.
Such data are important for the interpretation ofMMA
results by clinicians.
For the purpose of this study, pooled urine samples
of four MMA concentration levels have been prepared
in a professional setting (Chromsystems GmbH,
Munich, Germany). Samples are lyophilized and can
be shipped by regular postal services. Readers of
Clinical Chemistry and Laboratory Medicine are invit-
ed to join this pilot study. If they decide to do so, they
are asked to send an e-mail to Michael Vogeser, Uni-
versity of Munich (michael.vogeser@med.uni-muen-
chen.de) up until March 31, 2005 with the detailed
postal address of the participating laboratory; sam-
ples will be shipped within 1 week. Analysis results
can be submitted via e-mail. Six weeks after the end
of the shipment period the results will be processed
and the data (with mean concentrations reported and
distribution of results) will be sent to the participants.
The identity of the participants will not be given to
any third party.
It is planned to submit the results of this pilot study
as an article to Clinical Chemistry and Laboratory
Medicine. Demonstration of close inter-laboratory
agreement of urinary MMA measurement by an
international survey is, in our opinion, essential to
increase the limited acceptance of urinary MMA
measurement by clinicians, and thus has the potential
to improve patient care.
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